Background: Irritable bowel syndrome (IBS) is currently one of the most common disorders of the digestive system in the Western society. Almost 2 out of 10 people suffer from IBS with women being more affected than men. IBS is associated with abdominal pain, bloating and altered stool consistency and imposes a heavy burden for the affected patients. Summary: The pathophysiology of IBS remains elusive although potential causes have been suggested, such as a deranged brain-gut signaling, hypersensitivity of visceral sensory afferent fibers, bacterial gastroenteritis, small intestinal bacterial overgrowth (SIBO), genetic alterations and food sensitivity. Targets for the pharmacotherapy of IBS include the serotonergic and opioidergic system, and the microbial population of the gut. Alternative therapies like traditional Chinese medicine have shown some success in the combat against IBS. Key Messages: Many therapeutics for the treatment of IBS have emerged in the past; however, only a few have met up with the expectations in larger clinical trials. Additionally, the multifactorial etiology of IBS and its variety of cardinal symptoms requires an individual set of therapeutics. This review provides a short overview of potential causes and current pharmacological therapeutics and of additional and alternative therapies for IBS.

Keywords:
IBS, Functional bowel disorders, Pharmacological treatment
1.
Chey WD, Kurlander J, Eswaran S: Irritable bowel syndrome: a clinical review. JAMA 2015;313:949-958.
2.
Song SW, Park SJ, Kim SH, Kang SG: Relationship between irritable bowel syndrome, worry and stress in adolescent girls. J Korean Med Sci 2012;27:1398-1404.
3.
Mearin F, Baró E, Roset M, Badía X, Zárate N, Pérez I: Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol 2004;99:113-121.
4.
Viera AJ, Hoag S, Shaughnessy J: Management of irritable bowel syndrome. Am Fam Physician 2002;66:1867-1874.
5.
Whorwell PJ: What is irritable bowel syndrome? Therap Adv Gastroenterol 2012;5:379-380.
6.
Heaton KW, O'Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ: Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992;102:1962-1967.
7.
Srinath AI, Walter C, Newara MC, Szigethy EM: Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol 2012;5:339-357.
8.
Silk DB: Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol 2001;13:1327-1332.
9.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
10.
Bommelaer G, Dorval E, Denis P, Czernichow P, Frexinos J, Pelc A, Slama A, El Hasnaoui A: Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol Clin Biol 2002;26:1118-1123.
11.
Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M: Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil 2012;24:e853-e897.
12.
Camilleri M: Irritable bowel syndrome: how useful is the term and the ‘diagnosis'? Therap Adv Gastroenterol 2012;5:381-386.
13.
Black TP, Manolakis CS, Di Palma JA: ‘Red flag' evaluation yield in irritable bowel syndrome. J Gastrointestin Liver Dis 2012;21:153-156.
14.
Endo Y, Shoji T, Fukudo S: Epidemiology of irritable bowel syndrome. Ann Gastroenterol 2015;28:158-159.
15.
Saito YA, Schoenfeld P, Locke GR 3rd: The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-1915.
16.
Ng KS, Nassar N, Hamd K, Nagarajah A, Gladman MA: Prevalence of functional bowel disorders and faecal incontinence: an Australian primary care survey. Colorectal Dis 2014, Epub ahead of print.
17.
Lovell RM, Ford AC: Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-721.e4.
18.
Fass R: Irritable bowel syndrome: a global view. J Gastroenterol Hepatol 2003;18:1007-1009.
19.
Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ: A population-based epidemiologic study of irritable bowel syndrome in Guangdong province. Zhonghua Yi Xue Za Zhi 2004;84:278-281.
20.
Gwee KA, Lu CL, Ghoshal UC: Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 2009;24:1601-1607.
21.
Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW: The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400-406.
22.
Mearin F: Postinfectious functional gastrointestinal disorders. J Clin Gastroenterol 2011;45(suppl):S102-S105.
23.
Surdea-Blaga T, Băban A, Dumitrascu DL: Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol 2012;18:616-626.
24.
Rodríguez LA, Ruigómez A: Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:565-566.
25.
Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd: Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994;107:1040-1049.
26.
Gulewitsch MD, Enck P, Hautzinger M, Schlarb AA: Irritable bowel syndrome symptoms among German students: prevalence, characteristics, and associations to somatic complaints, sleep, quality of life, and childhood abdominal pain. Eur J Gastroenterol Hepatol 2011;23:311-316.
27.
Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ 3rd: Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907-912.
28.
Anbardan SJ, Daryani NE, Fereshtehnejad SM, Taba Taba Vakili S, Keramati MR, Ajdarkosh H: Gender role in irritable bowel syndrome: a comparison of irritable bowel syndrome module (ROME III) between male and female patients. J Neurogastroenterol Motil 2012;18:70-77.
29.
Longstreth GF, Preskill DB, Youkeles L: Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome. Dig Dis Sci 1990;35:1285-1290.
30.
Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G: Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-920.
31.
Drossman DA, Camilleri M, Mayer EA, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131.
32.
Lee BJ, Bak YT: Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252-266.
33.
Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S: Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512-519.e114-e115.
34.
Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A: The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
35.
Collins SM, Surette M, Bercik P: The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012;10:735-742.
36.
Camilleri M: Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012;367:1626-1635.
37.
Steck N, Mueller K, Schemann M, Haller D: Bacterial proteases in IBD and IBS. Gut 2012;61:1610-1618.
38.
Scanu AM, Bull TJ, Cannas S, Sanderson JD, Sechi LA, Dettori G, Zanetti S, Hermon-Taylor J: Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities. J Clin Microbiol 2007;45:3883-3890.
39.
Quigley EM, Quera R: Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006;130(2 suppl 1):S78-S90.
40.
Posserud I, Stotzer P, Björnsson ES, Abrahamsson H, Simrén M: Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56:802-808.
41.
Ghoshal UC, Srivastava D: Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol 2014;20:2482-2491.
42.
Stasi C, Rosselli M, Bellini M, Laffi G, Milani S: Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 2012;47:1177-1185.
43.
Bonaz B: Inflammatory bowel diseases: a dysfunction of brain-gut interactions? Minerva Gastroenterol Dietol 2013;59:241-259.
44.
Gershon MD: Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005;39:S184-S193.
45.
Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L: Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005;115:398-409.
46.
Elsenbruch S, Rosenberger C, Bingel U, Forsting M, Schedlowski M, Gizewski ER: Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 2010;139:1310-1319.
47.
Eswaran S, Tack J, Chey WD: Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am 2011;40:141-162.
48.
Chirila I, Petrariu FD, Ciortescu I, Mihai C, Drug VL: Diet and irritable bowel syndrome. J Gastrointestin Liver Dis 2012;21:357-362.
49.
Friedman G: Diet and the irritable bowel syndrome. Gastroenterol Clin North Am 1991;20:313-324.
50.
Dapoigny M, Stockbrügger RW, Azpiroz F, Collins S, Coremans G, Müller-Lissner S, Oberndorff A, Pace F, Smout A, Vatn M, Whorwell P: Role of alimentation in irritable bowel syndrome. Digestion 2003;67:225-233.
51.
El-Salhy M, Gundersen D: Diet in irritable bowel syndrome. Nutr J 2015;14:36.
52.
Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
53.
Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G: Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011;106:1290-1298.
54.
Philpott H, Gibson P, Thien F: Irritable bowel syndrome - an inflammatory disease involving mast cells. Asia Pac Allergy 2011;1:36-42.
55.
Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD: Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003;98:2454-2459.
56.
Yu SW, Rao SS: Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol 2014;7:193-205.
57.
Carter NJ, Scott LJ: Lubiprostone: in constipation-predominant irritable bowel syndrome. Drugs 2009;69:1229-1237.
58.
Khoshoo V, Armstead C, Landry L: Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:191-196.
59.
Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U: Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010;22:1402-1411.
60.
Tougas G, Snape WJ Jr, Otten MH, Earnest DL, Langaker KE, Pruitt RE, Pecher E, Nault B, Rojavin MA: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1701-1708.
61.
Tegaserod: withdrawal from the world market. A treatment for constipation with cardiovascular adverse effects. Prescrire Int 2008;17:112-113.
62.
Camilleri M, Kerstens R, Rykx A, Vandeplassche L: A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-2354.
63.
Emmanuel A, Cools M, Vandeplassche L, Kerstens R: Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol 2014;109:887-894.
64.
Olden KW: Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment. Cleve Clin J Med 2003;70(suppl 2):S3-S7.
65.
Mendzelevski B, Ausma J, Chanter DO, Robinson P, Kerstens R, Vandeplassche L, Camm J: Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol 2012;73:203-209.
66.
Thayalasekeran S, Ali H, Tsai HH: Novel therapies for constipation. World J Gastroenterol 2013;19:8247-8251.
67.
Evangelista S: Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Investig Drugs 2007;8:416-422.
68.
Wang SH, Lin CY, Huang TY, Wu WS, Chen CC, Tsai SH: QT interval effects of cisapride in the clinical setting. Int J Cardiol 2001;80:179-183.
69.
Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G: Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006;24:207-236.
70.
Aboumarzouk OM, Agarwal T, Antakia R, Shariff U, Nelson RL: Cisapride for intestinal constipation. Cochrane Database Syst Rev 2011;1:CD007780.
71.
Goldberg M, Li YP, Johanson JF, Mangel AW, Kitt M, Beattie DT, Kersey K, Daniels O: Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010;32:1102-1112.
72.
Cann PA, Read NW, Holdsworth CD, Barends D: Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-247.
73.
Jailwala J, Imperiale TF, Kroenke K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-147.
74.
Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M, Enck P, Frieling T, Haag S, Holtmann G, Karaus M, Kathemann S, Keller J, Kuhlbusch-Zicklam R, Kruis W, Langhorst J, Matthes H, Mönnikes H, Müller-Lissner S, Musial F, Otto B, Rosenberger C, Schemann M, van der Voort I, Dathe K, Preiss JC: Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 2011;49:237-293.
75.
Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-1159.
76.
Crutchley RD, Miller J, Garey KW: Crofelemer, a novel agent for treatment ofsecretory diarrhea. Ann Pharmacother 2010;44:878-884.
77.
Mangel AW, Chaturvedi P: Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008;78:180-186.
78.
Malcolm A, Camilleri M, Kost L, Burton DD, Fett SL, Zinsmeister AR: Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmacol Ther 2000;14:783-793.
79.
Bharucha AE, Fletcher JG, Camilleri M, Edge J, Carlson P, Zinsmeister AR: Effects of clonidine in women with fecal incontinence. Clin Gastroenterol Hepatol 2014;12:843-851.e2.
80.
Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, Baxter KL, Cox DS, Dukes GE, Kelleher DL, Zinsmeister AR: Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol Gastrointest Liver Physiol 2008;294:G1114-G1119.
81.
Schemann M, Hafsi N, Michel K, Kober OI, Wollmann J, Li Q, Zeller F, Langer R, Lee K, Cellek S: The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology 2010;138:266-274.
82.
Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J: Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171-1178.
83.
Klooker TK, Kuiken SD, Lei A, Boeckxstaens GE: Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:605-615.
84.
Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P: Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-378.
85.
Andresen V, Keller J, Pehl C, Schemann M, Preiss J, Layer P: Irritable bowel syndrome - the main recommendations. Dtsch Arztebl Int 2011;108:751-760.
86.
Sinagra E, Romano C, Cottone M: Psychopharmacological treatment and psychological interventions in irritable bowel syndrome. Gastroenterol Res Pract 2012;2012:486067.
87.
Morgan V, Pickens D, Gautam S, Kessler R, Mertz H: Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005;54:601-607.
88.
Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R: The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005;22:381-385.
89.
Salari P, Abdollahi M: Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol 2011;17:4251-4257.
90.
Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD: Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007;56:1218-1225.
91.
Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005;54:1402-1407.
92.
Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, Jin C, Grimes B, Pepin CJ: Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010;8:42-48.e1.
93.
Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P: Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313.
94.
Darvish-Damavandi M, Nikfar S, Abdollahi M: A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010;16:547-553.
95.
McKenzie YA, Alder A, Anderson W, Wills A, Goddard L, Gulia P, Jankovich E, Mutch P, Reeves LB, Singer A, Lomer MC; Gastroenterology Specialist Group of the British Dietetic Association: British dietetic asssociation evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012;25:260-274.
96.
Saxelin M, Tynkkynen S, Mattila-Sandholm T, de Vos WM: Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol 2005;16:204-211.
97.
Spiller R: Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:385-396.
98.
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35,624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590.
99.
Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, Kim YH, Kim JJ, Rhee JC, Rhee PL: Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714-2718.
100.
Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE: Long-term treatment with probiotics in primary care patients with irritable bowel syndrome - a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48:1127-1135.
101.
Basseri RJ, Weitsman S, Barlow GM, Pimentel M: Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2011;7:455-493.
102.
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
103.
Nayak AK, Karnad DR, Abraham P, Mistry FP: Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called ‘chronic amebiasis'. Indian J Gastroenterol 1997;16:137-139.
104.
Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y: Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006;51:1297-1301.
105.
Rezaie A, Nikfar S, Abdollahi M: The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010;6:49-55.
106.
Bolin TD: Use of oral sodium cromoglycate in persistent diarrhoea. Gut 1980;21:848-850.
107.
Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE: The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213-1221.
108.
Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP: Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:374-383.
109.
Lam C, Tan W, Leighton M, Hastings M, Lingaya M, Falcone Y, Zhou X, Xu L, Whorwell P, Walls AF, Zaitoun A, Montgomery A, Spiller R: A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut 2015, Epub ahead of print.
110.
Schicho R, Storr M: Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can J Gastroenterol 2011;25:377-383.
111.
Wilner LS, Arnold RM: Cannabinoids in the treatment of symptoms in cancer and AIDS #93. J Palliat Med 2006;9:802-804.
112.
Boesmans W, Ameloot K, van den Abbeel V, Tack J, Vanden Berghe P: Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol Motil 2009;21:e958-e977.
113.
Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G, Mascolo N, Di Marzo V, Capasso F: Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134:563-570.
114.
Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM: Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013;11:1276-1280.e1.
115.
Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA: Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit 2006;28:545-551.
116.
Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR: Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 2011;141:1638-1647.e1-e7.
117.
Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, Burton D, Zinsmeister AR: Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil 2012;24:358.e169.
118.
Rahimi R, Abdollahi M: Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol 2012;18:589-600.
119.
Tang ZP: Traditional Chinese medicine clinical experience of the treatment for irritable bowel syndrome. Chin J Integr Med 2009;15:93-94.
120.
Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE: Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med 2014;3:16-24.
121.
Wu J, Luo S: Jian shu wen qing tang used in the treatment for 60 cases of irritable bowel syndrome. J Tradit Chin Med 2004;24:100-101.
122.
Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L: Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2012;5:CD005111.
123.
Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B: Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006;4:CD005111.
124.
Gonsalkorale WM, Toner BB, Whorwell PJ: Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome. J Psychosom Res 2004;56:271-278.
125.
Pinn DM, Aroniadis OC, Brandt LJ: Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil 2015;27:19-29.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.